Next-Generation Antibodies for Inflammation and Cancer

SunRock Biopharma is advancing a pipeline of first-in-class antibodies, ADCs and bispecific programs across inflammatory diseases and oncology, with a lead therapeutic platform targeting CCR9.

The Company

Antibody Therapeutics Built Through Open Innovation

SunRock Biopharma transforms breakthrough academic science into differentiated antibody-based therapeutics for diseases with high unmet medical need. Through a global network of scientific, clinical and industrial partners, we advance first-in-class antibodies, ADCs and bispecific programs across inflammatory diseases and oncology

SRB Strategy

CCR9 Program

IBD

CCR9 plays a key role in inflammatory bowel disease by directing pathogenic lymphocytes to the intestinal tract. In active ulcerative colitis, its ligand CCL25 is detected in the colon and correlates with disease activity. Clinical studies have also shown increased levels of CCR9⁺ T cells in patients with IBD, supporting CCR9 as a highly relevant target for selective immune-cell modulation.

SunRock has developed SRB5, a novel anti-CCR9 antibody and with improved target affinity and increased antibody-dependent cellular cytotoxicity (ADCC) for the depletion of pathogenic T CCR9+ cells.

Oncology

Chemokine receptor 9, CCR9, is overexpressed in solid and hematologic tumors. CCR9 promotes metastatis and the development of resistance to conventional treatments in these tumors.

SunRock has partnered with Escugen Biotechnology TopoI inhibitor platform for the development of an anti-CCR9 antibody drug-conjugate (ADC) SRB123 for the treatment of solid tumors.

More info

HER3 Program

HER3 is a validated therapeutic target associated with tumor progression, reduced patient survival and the development of resistance to therapies directed against HER2 and EGFR.As part of the epidermal growth factor receptor family, HER3 plays a key role in the regulation of different tumor types and in the emergence of resistance to conventional treatments.

SunRock has developed an anti-HER3 molecule with improved affinity and a novel mechanism of action designed to overcome resistance and enhance anti-tumor efficacy compared with other anti-HER3 approaches.

More info